CD4+ T-cell activation (via tumor-specific MHC II) leads to increased interferon-gamma (IFN-γ) secretion, thus enhancing CXCL9 production and PD-L1 expression, culminating in an immunotherapy-sensitive tumor phenotype [41]. The gene discussed is CXCL9; the disease is neoplasm.